Photodynamic Therapy with Verteporfin for Choroidal Neovascularization of Pathologic Myopia in Japanese Patients: Comparison with Nontreated Controls

American Journal of Ophthalmology

Volumn 145, Issue 3, 2008, Pages

  Hayashi, Kengo ^a   Ohno Matsui, Kyoko ^a   Teramukai, Satoshi ^b   Shimada, Noriaki ^a   Moriyama, Muka ^a   Hara, Wakako ^a   Yoshida, Takeshi ^a   Tokoro, Takashi ^a   Mochizuki, Manabu ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

VERTEPORFIN;

ADULT; ANGIOGRAPHY; ARTICLE; CHORIORETINOPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; JAPAN; MALE; MYOPIA; OPHTHALMOSCOPY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 39149132796     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2007.10.032     Document Type: Article

References (34)

1. Yoshida T., Ohno-Matsui K., Ohtake Y., et al. Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups. Ophthalmology 109 (2002) 712-719
2. Yoshida T., Ohno-Matsui K., Yasuzumi K., et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 110 (2003) 1297-1305
3. Kojima A., Ohno-Matsui K., Teramukai S., et al. Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol 244 (2006) 1474-1479
4. Liu J.H., Cheng C.Y., Chen S.J., et al. Visual impairment in a Taiwanese population: prevalence, causes, and socioeconomic factors. Ophthalmic Epidemiol 8 (2001) 339-350
5. Ohno-Matsui K., Yoshida T., Futagami S., et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularization in pathologic myopia. Br J Ophthalmol 87 (2003) 570-573
6. Hsu W.M., Cheng C.y., Liu J.H., et al. Prevalence and causes of visual impairment in an elderly Chinese population in Taiwan: the Shihpai Eye Study. Ophthalmology 111 (2004) 62-69
7. Chan W.M., Ohji M., Lai T.Y., et al. Choroidal neovascularization in pathologic myopia: an update in management. Br J Ophthalmol 89 (2005) 1522-1528
8. Ku L., Wang Y., Li Y., et al. Causes of blindness and visual impairment in urban and rural areas in Beijing: the Beijing Eye Study. Ophthalmology 113 (2006) e1-e11
9. Cohen S.Y., Laroche A., Leguen Y., Soubrane G., and Coscas G.J. Etiology of choroidal neovascularization in young patients. Ophthalmology 103 (1996) 1241-1244
10. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial-VIP Report No. 1. Ophthalmology 108 (2001) 841-852
11. Blinder K.J., Blumenkranz M.S., Bressler N.M., et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: two-year results of a randomized clinical trial-VIP Report No. 3. Ophthalmology 110 (2003) 667-673
12. Virgili G., Varano M., Giacomelli G., et al. Photodynamic therapy for nonsubfoveal choroidal neovascularization in 100 eyes with pathologic myopia. Am J Ophthalmol 143 (2007) 77-82
13. Gelisken F., Inhoffen W., Hermann A., Grisanti S., and Bartz-Schmidt K.U. Verteporfin photodynamic therapy for extrafoveal choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol 242 (2004) 926-930
14. Krebs I., Binder S., Stolba U., Glittenberg C., Brannath W., and Goll A. Choroidal neovascularization in pathologic myopia: three-year results after photodynamic therapy. Am J Ophthalmol 140 (2005) 416-425
15. Schnurrbusch U.E.K., Jochmann C., Wiedemann P., and Wolf S. Quantitative assessment of the long-term effect of photodynamic therapy in patients with pathologic myopia. Graefes Arch Clin Exp Ophthalmol 243 (2005) 829-833
16. Pece A., Isola V., Vadala M., and Matranga D. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia. Retina 26 (2006) 746-751
17. The Japanese Age-Related Macular Degeneration Trial (JAT) Study Group. Japanese Age-Related Macular Degeneration Trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 136 (2003) 1049-1061
18. Lam D.S.C., Chan W.M., Liu D.T.L., Fan D.S.P., Lai W.W., and Chang K.K.L. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow-up. Br J Ophthalmol 88 (2004) 1315-1319
19. Pece A., Vadala M., Isola V., and Matranga D. Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in pathologic myopia: a long-term follow-up study. Am J Ophthalmol 143 (2007) 449-454
20. TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two year results of two randomized clinical trials-TAP Report No. 2. Arch Ophthalmol 119 (2001) 198-207
21. Ohno-Matsui K., Moriyama M., Hayashi K., and Mochizuki M. Choroidal vein and artery occlusion following photodynamic therapy in eyes with pathologic myopia. Graefes Arch Clin Exp Ophthalmol 244 (2006) 1363-1366
22. Montero J.A., and Ruiz-Moreno J.M. Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularization. Br J Ophthalmol 87 (2003) 173-176
23. Axer-Siegel R., Ehrlich R., Weinberger D., et al. Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: visual outcome in relation to age at treatment. Am J Ophthalmol 138 (2004) 602-607
24. Ergun E., Heinzl H., and Stur M. Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia. Am J Ophthalmol 138 (2004) 434-438
25. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia. 2-year results of a randomized clinical trial-VIP Report No. 3. Ophthalmology 110 (2003) 667-673
26. Schmidt-Erfurth U., Niemeyer M., Geitzenauer W., and Michels S. Time course and morphology of vascular effects associated with photodynamic therapy. Ophthalmology 112 (2005) 2061-2069
27. Stur M., and Ansari-Shahrezaei S. The effect of axial length on laser spot and laser irradiance. Arch Ophthalmol 119 (2001) 1323-1328
28. Prodi M.B., Da Pozzo S., and Ravalico G. Retinal pigment epithelium changes after photodynamic therapy for choroidal neovascularization in pathological myopia. Acta Ophthalmol Scand 85 (2007) 50-54
29. Avila M.P., Weiter J.J., Jalkh A.E., et al. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 91 (1984) 1573-1581
30. Cohen S.Y., Bulik A., Dubois L., and Quentel G. Photodynamic therapy for juxtafoveal choroidal neovascularization in myopic eyes. Am J Ophthalmol 136 (2003) 371-374
31. Lam D.S.C., Liu D.T.L., Lai W.W., So S.F., and Chan W.M. Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathologic myopia: 1-year results of a prospective series. Eye 19 (2005) 834-840
32. Sawa M., Ohji M., Gomi F., Kusaka S., Tano Y., and Bressler N.M. Apparent disappearance of choroidal neovascularization after initial photodynamic therapy with verteporfin. Arch Ophthalmol 120 (2002) 1588-1590
33. Sakaguchi H., Ikuno Y., Gomi F., et al. Intravitreal injection of bevacizumab for choroidal neovascularization associated with pathologic myopia. Br J Ophthalmol 91 (2007) 161-165
34. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization. Six-months results of a prospective study. Ophthalmology. Forthcoming.